Insulin therapy in type 2 diabetic patients: effects on arterial blood pressure and endothelin-1 plasma levels.
OBJECTIVE
To evaluate the possible effect of short- and long-term insulin treatment on arterial blood pressure (BP) and endothelin-1 (ET-1) plasma levels in type 2 diabetic patients.


METHODS
Seven type 2 diabetic patients with secondary failure to oral hypoglycemic drugs (SFOH) were studied. Twenty-four-hour arterial BP monitorization (Spacelabs 90207) was performed before initiation of insulin treatment (time 0), 6 days after (time 1) and 1 year later (time 2). Moreover, ET-1 plasma levels were measured.


RESULTS
Insulin treatment did not produce any variation in systolic (124.3 +/- 11.6; 120.7 +/- 7.9; 127.0 +/- 13.4 mmHg) and diastolic (72.8 +/- 5.9; 71.5 +/- 3.4; 71.8 +/- 5.2 mmHg) 24-h BP monitorization at times 0, 1 and 2, respectively. The systolic and diastolic day/night differences did not change in the three times studied. Neither were significant differences observed in ET-1 plasma levels.


CONCLUSIONS
In patients with SFOH, insulin treatment did not induce any short- or long-term increase in BP or any variation in plasma ET-1 levels.
Flores
L
L
Endocrinology and Diabetes Unit, Hospital Clinic, University of Barcelona, Spain.
Esmatjes
E
E
Manzanarez
J M
JM
Jiménez
W
W
Gomis
R
R
D000368:Aged; D000419:Albuminuria / Q000503:physiopathology; D001794:Blood Pressure / Q000187:drug effects* / Q000502:physiology; D001795:Blood Pressure Determination; D001824:Body Constitution; D015992:Body Mass Index; D002851:Chromatography, High Pressure Liquid; D002940:Circadian Rhythm; D003924:Diabetes Mellitus, Type 2 / Q000628:therapy*; D019332:Endothelin-1 / Q000097:blood*; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007328:Insulin / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012964:Sodium / Q000652:urine
D019332:Endothelin-1; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D012964:Sodium